In a 2023 safety report, the Civil Aviation Authority of Nepal...
Category:
Non-Life
Latest
Helicopter with 5 people on board crashes in the mountains northwest of Nepal’s capital
The four passengers are Chinese nationals, and the pilot is a...
FSIB to interview 5 candidates tom for selecting CMD of AIC
The general managers (GMs) who have been shortlisted on the basis...
Doubling time of coronavirus cases in India improves to 17.4 days: Health ministry
During the meeting with the cabinet secretary, the states were advised to focus on containment, testing and tracing, upgrading health infrastructure, clinical management and community engagement for effective management of COVID-19.
India’s vaccine shortage eases as inoculations outpace new registrations
Nearly half or 49% of the 60 and above population has been vaccinated with the first dose of Covid-19 vaccine. The percentage is 42% for those between 45 to 59 and 15% for those between 18-44 years. Total vaccine doses administered so far crossed the 33 crore mark on Tuesday.
Covea eyes take over of AXA XL Re
Any deal would make Thierry Derez’s mutual insurer Covéa finally realize its ambition to acquire a large global reinsurance operation and a takeover of AXA XL Re would strengthen its standings in the non-life reinsurance sector and diversify its offering.
Devas joins Cairn Energy in trying to seize Air India’s overseas assets
Calling the flagship airline an “alter ego” of the Indian state and therefore liable for the sovereign’s debts, Devas filed a petition in New York asking Air India to pay the amount or forfeit its U.S. property including planes, cargo handling equipment and artwork.
17 pc dip in average fresh COVID-19 cases since 2nd Corona wave peak in May, says Union Health Ministry
The Union Health Ministry further added that a total of 51 Delta plus variant cases reported in India. In regard to the Moderna COVID-19 vaccine, Dr VK Paul, Member-Health of Niti Aayog said, “New drug permission has been granted to Moderna, the first internationally developed vaccine. This new drug permission is for restricted use.”
GIC Re’s net profit rises 5 % to Rs 1260 crore, cuts gross premium 4% to Rs 8813 crore in Q4 Fy 21
With a combined ratio of 103.9 per cent(107.6 per cent), GIC Re’s underwriting loss has gone up by 15 per cent y-o-y to Rs 535 crore during the fourth quarter of Fy 2021.
The net investment income of the reinsurer has increased by 20 per cent y-o-y to R 2286 crore in the foutth quater of Fy 2021.For the whole of FY 2021,
SC orders implementation of ‘one nation, one ration card scheme’ by July 31
The bench directed the Centre to develop a portal with the help of the National Informatics Centre (NIC) for registration of unorganised sector workers for granting them the benefits of welfare schemes by July 31.
Cipla gets DCGI nod to import Moderna’s COVID-19 vaccine for restricted emergency use in India: Sources
According to the sources, approval is likely anytime as the Central Drugs Standard Control Organisation (CDSCO) is in favor of granting permission to Cipla for import of Moderna’s COVID-19 vaccine for restricted emergency use in India considering the pandemic situation in the country and the public interest.
Johnson & Johnson exploring ways to accelerate delivery of its COVID vaccine in India
‘We are in ongoing discussions with the Government of India and are exploring how best to accelerate our ability to deliver the Johnson & Johnson single dose COVID-19 vaccine to the people of India,” Johnson & Johnson India spokesperson said in a statement.
As per the recent announcement by the Drugs Controller General of India (DCGI), there is no longer a requirement to conduct bridging clinical studies of COVID-19 vaccines in India, the statement added.
Five Indian drugmakers to jointly start local trial of Merck & Co’s COVID-19 drug
Between March and April, each of these companies, including Sun Pharmaceutical Industries, Torrent Pharmaceuticals and privately held Emcure Pharmaceuticals, partnered with Merck to expand production of the drug, molnupiravir, hastening its availability in India to address a new wave of infections in the country.